Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Palantirs Q3 earnings and guidance are the dominant focus, with traders debating whether results can clear a high bar as AI stocks face a broader repricing. Bulls expect continued growth and an outlook increase, while bears argue that even a beat may not support the valuation without stronger guidance.

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

Anticipation of QUILT-2.005 Phase 3 results for ANKTIVA plus BCG in BCG-nave bladder cancer dominates discussion, alongside hopes that quarterly results will show continued commercial growth. Many traders see the data as a potential path to broader use after ANKTIVAs expanded bladder-cancer approval, while others question the efficacy outlook and competition; short-squeeze claims remain speculative.

Hyperliquids rally and repeated tests of record levels have traders focused on a push toward the $100 mark. Bulls point to fee-funded HYPE buybacks and growing institutional or regulated-market access as support for the tokens market story, while others warn of pullbacks and selling pressure.

Salesforce is caught in the broader debate over whether AI agents will weaken seat-based SaaS software or deepen reliance on established enterprise platforms. Traders connect pressure on CRM to sector-wide software weakness, including spillover from ServiceNow, while others see the pullback as an opportunity and argue Salesforces entrenched workflows can adapt to AI.

Zscaler is pulling back after recent highs as traders point to broader cybersecurity and software selling following Fortinets earnings reaction, alongside concerns about sector valuations. Some view the decline as a buying opportunity and cite call-heavy options activity, while others are cautious about Zscalers slower growth outlook and executive-transition overhang.

Oracles sharp selloff and failure to hold a rally after its Investor Day update are fueling debate over its debt-funded AI data-center expansion, heavy capital spending, and whether its large backlog will convert into cash flow. Bulls point to managements cash-flow and spending plans as evidence of a path forward, while bears remain concerned about financing risk and AI demand, with weakness in other major tech stocks adding pressure.

Zevra is drawing attention around its Q3 results and the pending CHMP re-examination of MIPLYFFA for Niemann-Pick type C, with FDA feedback on celiprolol also viewed as a potential catalyst. Traders are weighing confidence in U.S. commercial growth against skepticism about a favorable European regulatory outcome and concerns about management execution.

IBB is drawing attention amid a biotech-sector rebound and perceived rotation from technology and semiconductors into healthcare; traders highlight the ETFs resilience near highs, while some caution that the rally may pause and smaller biotech names remain more volatile.

Concerns about Big Tech earnings and whether heavy AI spending will generate adequate returns are weighing on the Magnificent Seven basket, with traders debating whether MAGS weakness is a temporary rotation into semiconductors or a deeper correction. Some see the pullback as a buying opportunity, while bearish voices cite strained cash flow and uncertain AI economics.